What Scribe Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 9 |
| Sells | 0 | 0 |
| Total trades | 1 | 14 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 5,798,552 |
| Disposed | 0 | 0 |
| Net activity | +0 | +5,798,552 |
Common stock only — 3 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Aghazadeh Behzad | Director | Jul 28 | Open-market buy · P | +7,905 | $18.25 | +$144K | 3,088,888 |
| Orbimed Advisors Llc | Director | Jul 27 | Open-market buy · P | +1,000,000 | $15.00 | +$15M | 1,348,825 |
| Orbimed Advisors Llc | Director | Jul 27 | Derivative Conversion · C | +348,825 | — | — | 348,825 |
| Ah Bio Fund II, L.p. | 10% owner | Jul 27 | Open-market buy · P | +333,333 | $15.00 | +$5M | 2,385,075 |
| Ah Bio Fund II, L.p. | 10% owner | Jul 27 | Derivative Conversion · C | +697,650 | — | — | 697,650 |
| Ah Bio Fund II, L.p. | 10% owner | Jul 27 | Derivative Conversion · C | +2,051,742 | — | — | 2,051,742 |
| Gordon Carl L | Director | Jul 27 | Open-market buy · P | +1,000,000 | $15.00 | +$15M | 1,348,825 |
| Gordon Carl L | Director | Jul 27 | Derivative Conversion · C | +348,825 | — | — | 348,825 |
| Doudna Jennifer A | 10% owner | Jul 27 | Derivative Conversion · C | +12,511 | — | — | 603,547 |
| Aghazadeh Behzad | Director | Jul 24 | Open-market buy · P | +50,000 | $22.31 | +$1.12M | 3,080,983 |
| Aghazadeh Behzad | Director | Jul 24 | Open-market buy · P | +2,333,333 | $15.00 | +$35M | 3,030,983 |
| Lucas Svetlana | Chief Business Officer | Jul 23 | Open-market buy · P | +3,000 | $15.00 | +$45K | 3,000 |
| Parrot David | Chief Financial Officer | Jul 23 | Open-market buy · P | +1,333 | $15.00 | +$20K | 1,333 |
| Parrot David | Chief Financial Officer | Jul 23 | Open-market buy · P | +1,333 | $15.00 | +$20K | 1,333 |
Loading...
